Infigratinib vs Other FGFR Inhibitors Efficacy and Sourcing in Precision Oncology
Author: Dr. Sarah Mitchell
On September 14, 2026, leading oncology networks reviewed comparative efficacy data for fibroblast growth factor receptor (FGFR) inhibitors. For patients diagnosed with advanced cholangiocarcinoma harboring FGFR2 fusions, choosing between targeted therapies like Infigratinib, Pemigatinib, and Futibatinib is a key clinical decision.
At Onco Medicine, we cooperate with international supply corridors to deliver authentic, batch-verified FGFR inhibitors to oncology clinics globally.
Comparing FGFR Inhibitors
Understanding the clinical differences helps oncologist tailor targeted therapies:
- Infigratinib (Lucinfig): A highly selective, oral tyrosine kinase inhibitor designed to block FGFR1-3 receptors, showing significant clinical responses in patients with FGFR2 fusions.
- Pemigatinib (Pemazyre): Another approved oral FGFR1-3 inhibitor, sharing a similar safety profile but with distinct dosing schedules.
- Futibatinib (Lytgobi): An irreversible, covalent FGFR1-4 inhibitor, often used in patients who develop resistance to reversible inhibitors.
Email our compliance team at support@onco-medicine.com or chat via WhatsApp +91 94275 19809.
